












































Mitochondrial DNA (mtDNA) is a small, double-
stranded circular molecule of 16,569 bp that is 
contained in many copies inside mitochondria, 
packaged into multimeric complexes called nucleoids 
made up of proteins and nucleic acids [1]. MtDNA 
molecules are particularly exposed to the reactive 
oxygen species (ROS)  that are formed  by  the  income- 
 
 












































plete oxygen reduction due to electron leakage from the 
transport chain and therefore are very susceptible to 
oxidative damage as well as to other mutagenic lesions, 
also because of a limited capability of their repair 
systems [2].  
 
A key molecule for mtDNA stability is polymerase 
gamma (polg), which is the sole mitochondrial 
polymerase and plays an essential role in both 
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is a heterotrimer that contains a 140 kDa catalytic 
subunit and a homodimer of accessory subunits. A polg 
defective in proofreading activity has been associated to 
a phenotype of accelerated aging in a murine model 
[5,6]. Alterations in the polymerase and exonuclease 
activity of polg induce an increase in the frequency of 
mtDNA mutations [3,7] and mutations of POLG1 gene 
are associated with a number of diseases [8-10]. Data 
also suggest that polg is likely involved in the aging 
process [11] and in the pathogenesis of a series of 
diseases in which mtDNA instability plays a pathogenic 
role, such as age-associated sarcopenia and Parkinson’s 
Disease [12,13]. Nevertheless, the molecular details by 
which polg ensures mtDNA integrity are still to be 
elucidated. 
 
It has been reported that p53 plays a role in the 
maintenance of mtDNA integrity [14-17]. TP53 gene 
has a well-known crucial role in the response to DNA 
damage, in cell cycle regulation, apoptosis and cell 
senescence. Recent studies from our and other 
laboratories demonstrated that p53 protein, the product 
of TP53 gene, in response to an oxidative stress not 
only behaves as a transcription factor at nuclear level, 
but can also translocate at mitochondrial level [18-20]. 
In the mitochondria, p53 could bind to Bcl-xL and to 
other proteins to induce mitochondrial-mediated 
apoptosis independently from transcriptional activity 
[18-21]. Moreover, it has been observed that a fraction 
of p53 is present in mitochondria of non-stressed cells 
[21]. It has been reported that within mitochondria p53 
can bind to polg and modulate its activity [14,15]. 
Indeed, it has been observed that in TP53 knock out 
animals the base excision repair activity is less efficient, 
and that p53 can bind to polg in in vitro cellular models, 
increasing polg-mediated mtDNA replication and 
suppressing the mutagenic effect of ROS and ethidium 
bromide [14,15,22]. It is also reported that in mtDNA at 
least one consensus sequence for p53 binding does exist 
[23].  
 
TP53 gene has a number of natural allelic variants, 
among which those due to the polymorphism at codon 
72 (in the exon 4) are of particular interest. This 
common polymorphism causes a C-to-G transversion 
that in turn leads to a Proline-to-Arginine substitution in 
the p53 protein. The two resulting variants (p53P
72 and 
p53R
72) are different as far as the capability to modulate 
apoptosis, to translocate to mitochondria, to be 
degraded by proteasome and to bind to MDM2 [24-27]. 
It has been observed that these differences become 
significant in ex vivo models as the age of the donor 
increases, being negligible in cells from young donors, 
and statistically significant in cells from old people and 
centenarians [20,28]. The in vivo functional importance 
of such a polymorphism is demonstrated by the fact that 
p53R
72 homozygotes and p53P
72 carrier subjects have a 
different survival after age 85 (greater for p53P
72 
carriers) as well as a different cancer incidence and 
survival after cancer diagnosis [29-31].  
 
It has been reported that p53P
72 is more able than 
p53R
72 in promoting nuclear DNA repair [32]. Since as 
summarised above the two p53 isoforms have a 
different tendency to localise at mitochondria, we then 
wondered whether they can differ also in capability to 
maintain mtDNA stability, and whether this may occur 
through a differential binding to mtDNA replisome 
components such as polg. To check this hypothesis we 
performed  in vitro as well as in vivo studies whose 





72 localises with extranuclear 8-oxo-dG more 
than p53P
72 and protects mitochondrial function 
 
We could confirm that, as previously reported for ex 
vivo cells [20], also ectopically expressed p53 tends to 
localise differently according to the polymorphism at 
codon 72. Figure 1 shows the confocal analysis of p53 
null HCT116 cells transfected with pCMS-EGFP 
plasmid, either empty or expressing the arginine or 
proline TP53 allele. Three representative cells are 
presented. It can be appreciated that upon treatment 
with 100 nM rotenone (an inhibitor of mitochondrial 
respiration complex I) for 24 hours, while cells 
transfected with the empty vector resulted to have a 
widespread EGFP fluorescence not clearly associated 
with any subcellular structure (upper panels), cells 
transfected with p53R
72-expressing plasmid showed a 
dotted EGFP fluorescence largely overlapping with 
MitoTracker Red CMX-Ros (MTR) fluorescence 
specific for mitochondria (central panels), a 
phenomenon which is much less evident when p53P
72-
expressing plasmid is used (lower panels).  
 
Upon treatment with rotenone, we observed by confocal 
microscopy and flow cytometry (Figure 2A and 2B) a 
consistent accumulation of 8-oxo-dG fluorescence, 
which appears to be localised outside the nucleus of 




plasmids, we observed that upon rotenone treatment 
p53R
72 tends to co-localise with 8-oxo-dG extranuclear 
fluorescence more than p53P
72 (Figure 2C, arrows). On 
the other side, p53P
72 has a preferential nuclear 
localisation, as showed by the perfect overlap with 
Hoechst staining. This indicates that rotenone treatment 
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organelle bearing extranuclear DNA, and that p53R
72 































































MitoTracker  Red  (MTR).  Cells  transfected  with  the 
empty vector show a diffused EGFP fluorescence, not 
associated with any cell structure; in cells transfected 
with  the  plasmids  expressing  the  p53  isoforms,  a 
different subcellular localisation is noticed, as assessed 
by  counter‐staining  with  the  mitochondrial‐specific 
probe  MTR.  In  particular,  when  EGFP‐p53R
72  pCMS 
plasmid is used, EGFP fluorescence, associated to p53
protein,  appears  to  be  not  nuclear  but  rather  co‐
localised  with  MTR  fluorescence,  indicating  that  p53 
has  a  mitochondrial  localisation  (white  dots  indicate 
points of overlapping of the two fluorescences).  
 




and  revealed  with  RPE‐conjugated  secondary  moAb 
(red  fluorescence).  Nuclei  are  counterstained  with 
Hoechst  33258.  Punctuated,  cytoplasmic  red 
fluorescence  indicates  that  8‐oxo‐dG  accumulates  in 
mitochondria but not nuclei upon rotenone treatment. 







8‐oxo‐dG  (red  fluorescence)  and  p53  (green 
fluorescence)  co‐localise  (yellow  dots  in  the  merged



















































In order to have a semi-quantitative evaluation of the 
accumulation of 8-oxo-dG in cells transfected with 
either EGFP-p53R
72 or EGFP-p53P
72 we set up a flow 
cytometric test in which transfected HCT116 cells were 
treated with rotenone 100nM for 24 hours and then 
immunostained with anti-8-oxo-dG moAb. Cells 
positive for EGFP (expressing p53) were electronically 
gated and compared for 8-oxo-dG specific fluorescence 
(RPE fluorochrome) with EGFP-negative cells (not 
expressing p53). Results are reported in Figure 3, where 
a representative experiment is reported together with 
mean ± st.dev. of three separate experiments. Figure 3A 











































for both plasmids. Cells considered EGFP-positive are 
gated in Region 1 (R1) and represented in red dots. 
Figure 3B shows the 8-oxo-dG fluorescence of cells not 
gated in R1 (upper panels) and gated within R1 (lower 
panels). As shown, EGFP-p53-negative cells (not R1) 
are almost all positive for 8-oxo-dG fluorescence (more 
than 90%), no matter of the plasmid used for the 
transfection procedure (EGFP-p53R
72 pCMS vs EGFP-
p53P
72  pCMS, p=0.34, two-tailed Student’ t test). On 
the contrary, when considering EGFP-p53-positive cells 
(R1), the percentage of cells positive for 8-oxo-dG is 
quite different depending on the p53 isoform the cells 
are transfected with. Indeed, this percentage is 
Figure  3.  Flow  cytometry  analysis  of  p53
‐/‐ HCT116  cells 









8‐oxo‐dG  fluorescence  (RPE).  Numbers  represent  the 
percentage of cells with high 8‐oxo‐dG fluorescence and are 
expressed  as  mean  ±  st.  dev.  of  three  independent 
experiments.  As  showed  EGFP‐negative  cells  (not  R1,  not 
expressing  p53)  are  almost  all  positive  for  8‐oxo‐dG 
fluorescence (more than 90%), while when considering EGFP‐
positive  cells  (R1,  expressing  p53),  the  cells  that  were 
transfected with p53R
72 which resulted positive for 8‐oxo‐dG 
decreased  to  69%,  with  respect  to  92%  of  those  that  were 
transfected  with  p53P
72.  See  text  for  comment.  (C)
Mitochondrial membrane potential (MMP) analysis. The cells 
in (R1) were evaluated for MMP by using the potentiometric 
dye  TMRM.  Black  line:  control  cells;  red  line:  rotenone 
treatment. Decrease in MMP was expressed as the difference
(Δ) of TMRM fluorescence intensity between rotenone‐treated 
and  control  cells.  Cells  positive  for  EGFP‐p53R
72  (left  panel) 
display  a  lower  decrease  in  MMP  with  respect  to  those 
positive for EGFP‐p53P
72 (right panel). The graphic shows data 
related  to  3  independent  experiments  (mean  ±  st.  dev.)  * 
Student’ t test p= 0.022. NT, not transfected. 
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72 
isoform with respect to those expressing the p53P
72 one 
(69.6 ± 1.6 vs 92.1 ± 4.5, p=0.003). An analysis of 
Mitochondrial Membrane Potential (MMP) made with 
the potentiometric dye TMRM also indicated that 
EGFP-p53R
72-positive cells are less susceptible to 
undergo MMP decrease with respect to those positive 
for EGFP-p53P
72, suggesting that these cells have a 
better preserved mitochondrial function (Figure 3C). 
 
p53R72 binds to polg more than p53P72 and 
protects mtDNA integrity  
 
A possible mechanism to explain this difference could 
be the reported different capability of the two p53 
isoforms to induce apoptosis, so that heavily damaged 
cells transfected with p53R
72 isoform would be more 
prone to apoptosis than those transfected with p53P
72, 
but this seems not to be the case. Indeed, transfection 
appears to induce massive apoptosis, but with no 
difference between the two plasmids (data not shown). 
Another possible mechanism is the different capability 
of the two isoforms to localise at mitochondrial level. 
This may favour the binding and activation of polg, the 
polymerase involved in mtDNA repair. We then 
checked the co-localisation of p53 isoforms with polg. 
After checking for  anti-polg antibody specificity 
(Figure 4A), we found that EGFP-p53R
72 co-localises 
with polg more than EGFP-p53P
72 (Figure 4B, arrows).  
 
To further strengthen these data, we generated stably 
transfected PC3 cells expressing either p53R
72 or 
p53P
72, conjugated with HA epitope tag, and performed 
co-immunoprecipitation assay (Figure 4C). To this 
purpose, cells were exposed to10 nM rotenone, for 72 
hours then protein were precipitated for polg and 
assayed with anti-HA antibody. These experiments 
confirmed that p53R
72 is more bound to polg than 
p53P
72. The experiment was repeated with different 
exposure times. Other than 72 hours exposure, cells 
were treated for 6 or for 6 hours then recovery until 72 
hours (6h+r). Also in this case p53R
72 resulted to be 
more bound to polg than p53P
72  except that
  at point 
6h+r (Figure 4D). 
 
It is reported that mutator mice with a polg deficient in 
proofreading activity accumulate both mtDNA point 
mutations and deletions [33]. We then checked whether 
exposure to rotenone in cells expressing either one or 
the other p53 isoform could induce an accumulation of 
mtDNA damage such as large deletions (e.g. the 4,977 
bp), assessed by nested PCR and Long PCR. Also, since 
this deletion leads to an increase in mtDNA copy 
number [34], we also checked whether mtDNA copy 
















































stably transfected cells. These tests were performed on 
total DNA extracted from stably transfected PC3 cells 
before and after treatment with 10 nM rotenone. No 
difference in terms of mtDNA copy number was 
observed (Figure 5A), even if a trend of higher copy 
number is present for p53P
72 expressing cells. 
Nevertheless, both Nested PCR and Long PCR 




‐/‐  HCT116  non‐transfected  cells  stained  with  anti‐polg
antibody  alone  or  with  the  TRITC‐conjugated  secondary
antibody;  Western  Blot  analysis  of  specificity  of  the  anti‐polg
antibody on cytoplasmic and nuclear fractions obtained from HL‐




cells  transfected  with  EGFP‐p53R
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expressing p53R





















































As a whole, these data suggest that TP53 codon 72 
polymorphism affects accumulation of damage in 
mtDNA likely by modulating the efficiency of mtDNA 
repair. Data presented in this paper suggest that this 
modulation occurs through the binding of p53 to polg, 
even if other possible mechanisms can not be excluded.  
 
TP53 codon 72 polymorphism is associated with 
mtDNA heteroplasmy in vivo 
 
In order to investigate whether TP53 codon 72 
polymorphism has an impact on mtDNA stability in 
vivo, thus reflecting the differences we observed for the 
two isoforms in vitro, we analysed the correlation 
between mtDNA heteroplasmy and TP53 codon 72 
genotype in white blood cells (WBC) from 425 
volunteers of old age (from 60 to 108 years of age), 
where accumulation of somatic mtDNA mutations are 
more likely to occur. Heteroplasmy was assessed by 
DHPLC in a segment of the mtDNA D-loop from nt 
16531 to nt 261, spanning between hypervariable region 
(HVR) 1 and 2. Table 1 shows the distribution of 
mtDNA heteroplasmy in subjects with different 
genotypes at TP53 codon 72. We found that subjects 
with different level of heteroplasmy are not randomly 
distributed across the three genotypes (p=0.0147). In 
particular, considering a heteroplasmy threshold of 5%, 
we observed that homozygous TP53R
72/R
72 subjects 
with a heteroplasmy over 5% are less frequent than 
expected, while heterozygous subjects with a 
heteroplasmy over 5% are more frequent than expected. 
A univariate logistic analysis, where the genotype at 
TP53 codon 72 was the independent variable and the 
presence/absence of high level of heteroplasmy was the 
dependent variable, showed that p53R
72 acts as a 
recessive allele on the trait presence/absence of high 
level of heteroplasmy. On the whole these data suggest 
that homozygous TP53R
72/R
72 genotype is associated 
with lower accumulation of heteroplasmy in the 


















and  recovery  until  72h  (6h+r).  (A)  copy  number  assessed  by
Real‐time PCR. Data are expressed as ratio between the levels of
ND1  and  actin  genes,  and  are  the  average  value  of  three
separate  measurements  ±  st.  dev.  White  columns:  p53R
72
expressing  cells;  black  columns:  p53P




















  Obs (%)  Exp    Obs (%)  Exp    Obs (%)  Exp     
≤ 5%  127 (57.2)  116 
 
75 (33.8)  87.2 
 
20 (9.0)  18.8 
 
222 
> 5%  95 (46.8)  106 
 
92 (45.3)  79.8 
 
16 (7.9)  17.2 
 
203 
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mtDNA integrity tends to decrease with age, as 
demonstrated by the accumulation of point mutations 
and deletions in a variety of tissues during aging in 
humans, monkeys, and rodents [35,36]. The 
accumulation of somatic mtDNA mutations has likely a 
causative role in the aging of the organisms, as 
suggested by animal models such as the mutator mice 
lacking the proofreading activity of polymerase gamma 
(polg) [5,6,37]. Therefore, it is reasonable to 
hypothesise that factors impinging upon the stability of 
mtDNA can affect the rate of aging in animals and 
humans. 
 
p53 has a well-known role in inducing DNA repair, 
apoptosis, block of cell cycle and induction of cell 
senescence. More recently, other roles have been 
discovered for p53, regarding autophagy, glucose 
metabolism and miRNA maturation [37-40]. Among 
these new functions, a role in controlling mtDNA 
replication and repair has been proposed for p53 
through the binding of polg [15] and TFAM [41]. As 
summarised above, it is known that human TP53 is 
characterised by a polymorphism at codon 72 that yields 
two isoforms of the p53 protein differing by one 
aminoacid at the level of the N-terminus Proline Rich 
Region, and that these two isoforms differ in the 
capability to localise within the cell. Since one of these 
two isoforms (p53R
72) can efficiently localise at 
mitochondrial level, we wondered whether in cells 
bearing this isoform, the accumulation of alterations at 
the level of mtDNA was lower than in cells bearing the 
other isoform (p53P
72), and whether this could have an 
in vivo consequence on the accumulation of mtDNA 
mutations. As a whole, our data suggest that this is the 
case. The mechanism by which this occurs seems to be 
an interaction of p53 with polg. We can not exclude, 
however, that other possible mechanisms take place 
simultaneously. For instance, it is reported that p53 
binds also to HmtSSB and that this binding slightly 
increases the exonuclease activity of p53 capable to 
eliminate 3’- 8-oxo-dG nucleotides [42]. Also the 
binding to TFAM likely renders mtDNA more 
accessible to repair enzymes [17]. 
 
As a whole, the data reported in this paper and other 
present in the literature suggest that the two isoforms 
p53P
72 and p53R
72 are more prone to ensure the repair 
of the nuclear or the mitochondrial genome, 
respectively. Indeed, it has already been reported that 
cells that express in vitro the p53P
72 isoform have a 
greater capability to repair damages of nuclear DNA 
and display a reduced production of micronuclei with 
respect to cells that express the p53R
72 isoform [32]. 
Thus, it seems that the capability to localise at 
mitochondria can affect not only the activity of p53 as 
an inducer of transcription-independent apoptosis, but 
also as a cofactor of mtDNA repair, therefore 
influencing mtDNA stability and eventually 
mitochondrial efficiency. 
 
To test whether these in vitro findings have an in vivo 
counterpart, we analysed the levels of mtDNA 
heteroplasmy in WBC from subjects with different 
genotype at TP53 codon 72. Indeed we found that 
subjects with p53R
72/R
72 genotype have a lower chance 
to accumulate heteroplasmy in the mtDNA control 
region (CR), suggesting that also in vivo this 
polymorphism has an effect on mtDNA stability. 
Previous studies had shown that the accumulation of 
somatic mutations in the mtDNA CR is genetically 
influenced by nuclear genome variability [43,44]. The 
variability of TP53 codon 72 may then be part of the 
genetic “machinery” affecting the accumulation of 
mtDNA somatic mutations.  
 
It is to note that in previous reports, high levels of 
heteroplasmy in the mtDNA CR seem to be a genetic 
characteristic of human longevity, being present in 
centenarians and their offspring [43,44] as well as in 
90+ sibpairs [45]. This may suggest that mtDNA 
heteroplasmy should not to be considered detrimental in 
all cases, being possible that certain types of 
heteroplasmy can provide the cell with some (still 
unknown) type of survival signalling. As an example, 
the substitution at position 150 of mtDNA CR found in 
centenarians seems to favour mtDNA replication [43]. 
If this is true, one may expect that TP53 codon 72 
polymorphism can affect the survival at old age through 
the capability to control, at least in part, the level of 
heteroplasmy of the mtDNA CR. Previous studies from 
our group indicate that TP53 codon 72 polymorphism 
does not affect the human lifespan, when large cohorts 
of subjects from young people to centenarians are 
analysed [46]. However, when a more restricted age 
range is considered, it appears that 85+ subjects 
carrying the TP53P
72/P
72  genotype have a survival 
advantage over those carrying the TP53R
72/R
72 
genotype [30]. We surmise that the effect of the TP53 
codon 72 polymorphism on the level of mtDNA CR 
heteroplasmy might contribute to this survival 
advantage. Further investigations are needed to test 
whether this hypothesis is correct. 
 
MATERIALS AND METHODS 
 
Cells culture and treatment. p53 null HCT116 cells 
were a kind gift of Bert Vogelstein (Sidney Kimmel 
Comprehensive Cancer Center, Johns Hopkins 
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in McCoy’s medium, pH 6.9, supplemented with 10% 
FCS and penicillin (100 units/mL)/streptomycin (100 
m g / m L )  i n  5 %  C O 2 humidified atmosphere at 37°C. 
They were collected at log phase of growth, counted 
and seeded in 6-wells plates at the concentration of 
50,000/ml (total volume 2 ml). After 48 hours of 
culture, medium was changed and the cells were 
transiently transfected with 3 ng of pCMS-EGFP 
plasmid, either empty or expressing the EGFP-p53R
72 
or EGFP-p53P
72 allele, using JetPEI transfection 
reagent (Polyplus transfection) according to the 
manufacturer instructions for additional 24 hours, after 
which 100 nM rotenone was added and left to stay for 
24 hours unless otherwise indicated. After this time 
cells were collected and analysed by either confocal 
microscopy or flow cytometry. In set-up experiments 
cells were analysed for the level of apoptosis by 
staining with Propidium Iodide (PI) in hypotonic 
solution as previously described [28]. Analysis was 
performed in linear scale in order to detect also possible 
accumulation in G2 phase. No difference in terms of 
percentage of apoptotic cells was found between cells 
transfected with either EGFP-p53R
72 or EGFP-p53P
72 
expressing plasmids; accumulation in G2 was also not 
observed under rotenone treatment (data not shown). 
 
Confocal microscopy.  After treatment, cells were 
collected and stained by immunocytochemistry for polg 
or 8-hydroxy-2’-deoxyguanosine (8-oxo-dG). Briefly, 
cells were seeded into wells containing a sterile glass 
coverslip for confocal microscopy. After the treatments 
(see above), cells were washed with PBS+1% BSA, 
fixed in formaldehyde 2% in PBS for 10 minutes at RT 
and permeabilised with saponin 0.2% in PBS for further 
10 minutes at RT. For polg detection, cells were 
incubated with anti-polg rabbit polyclonal antibodies 
(Pierce) (dilution 1:200) for 1 hour at 4°C and goat-anti-
rabbit TRITC-conjugated IgG(H+L) (BioFX 
Laboratories) (dilution 1:400) for 1 hour at 4°C. 
Coverslips were then mounted onto a glass slide with 
mowiol, sealed and kept at 4°C in the dark until 
confocal analysis. For 8-oxo-dG detection, after fixation 
and permeabilisation, the cells were treated with 2N 
HCl for 30 minutes at RT, followed by pH re-
equilibration with Borax solution 0.1M. Slides were 
then washed with PBS+1% BSA and incubated with 
anti-8-oxo-dG mouse monoclonal antibodies (Trevigen) 
(dilution 1:1000) for 4 hours at 4°C and goat-anti-
mouse RPE-conjugated monoclonal antibody (Dako) 
(dilution 1:250) for 1 hour at 4°C. In some experiments, 
bis-benzimide (Hoechst 33258) 250ng/ml was added to 
counterstain nuclei. Slides were analysed with a “Leica 
DMIRE2” inverted research microscope connected with 
a TCS SP2-AOBS system (Leica, Germany) equipped 
with blue COH diode (405nm/25mW), Ar 
(458nm/5mW) (476nm/5mW) (488nm/20mW) 
(496nm/5mW) (514nm/20mW), HeNe 
(543nm/1.2mW), HeNe (594nm) (Orange) and HeNe 
(633nm/102mW) lasers. The microscope and the AOBS 
system were controlled by the LCS software (Leica). 
The slides were observed under a HCX PL APO 
40x/1.25 – Oil- objective. In order to avoid overlaps 
between fluorochrome excitations/emissions during 
scanning procedures, images where acquired in separate 
channels for each fluorochrome. Merged figures derived 
from the software-assisted integration of horizontal 
xyλ-sections (line average= 2; number of scansions per 
line= 3). Colocalisation of different fluorochromes was 
ascertained using the measuring and analysis functions 
of LCS software Version 2.0, 2001 (Leica, Germany). 
 
Flow cytometry.  Cytofluorimetric analyses were 
performed using a FACScalibur cytometer (BD), 
equipped with an argon laser on a minimum of 10,000 
cells per sample, acquired in list mode. Briefly, cells 
were detached from substrate with 1% trypsin in PBS 
for 2 minutes and treated as described for 8-oxo-dG 
detection. Analysis of 8-oxo-dG specific fluorescence 
was performed on cells electronically gated for being 
positive for EGFP fluorescence (meaning that they are 
expressing p53) and compared to those negative for 
EGFP (meaning that they are not expressing p53) in the 
same sample, thus avoiding experimental variability. 
The experiments were repeated three times. 
Mitochondrial Membrane Potential (MMP) was 
assessed by using the potentiometric dye Tetramethyl-
rhodamine methyl esther, perchlorate (TMRM, 
Molecular Probes). Staining with 150 nM TMRM for 
15 min at room temperature was followed by washing 
in PBS and analysis. Multiparametric analysis allowed 
for the simultaneous detection of TMRM (red) and 
EGFP (green) fluorescences.  
 
Generation of stable transfectant. In order to obtain a 
higher percentage of transfected cells, we generated 
stably transfected cell lines expressing the two p53 
isoforms using PC3 p53 null cells. An HA-epitope tag 
was added to the N-terminal position of p53 cDNA 
sequence of both codon 72 Arginine and Proline 
isoforms using PCR with the following primers: 
Forward, p53 NotI HA tag 5'- GCG GCC GCG GCG 
CGC CCG GGA TCC TGA TCA GCA GGC GCC 
ATG TAC CCA TAT GAT GTT CCA GAT TAC GCT 
GAG GAG CCG CAG TCA GAT CCT -3'; Reverse, 
p53 BglII site 5'- GCA GAT CTA TTT AAT TCA GTC 
TGA GTC AGG CCC TTC T -3'.  The restriction sites 
NotI and BglII were used to ligate the PCR product into 
the retrovector LNXCO3 that supports IPTG inducible 
expression. 
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the murine ecotropic retrovirus receptor and LacI 
repressor genes as previously described [47]. The 
LNp53CO3 vector for both isoforms was constructed by 
cloning the entire coding sequence of the human p53 
cDNA in the NotI and BglII sites of IPTG-inducible 
retroviral vector LNXCO3 [47]. Insert-free vector 
LNXCO3 was used for control infections. Both 
isoforms of LNp53CO3 and LNXCO3-transduced cell 
populations were selected with 600ug/ml G418. Cell 
lines were cloned by plating 500-2000 cells per 150 mm 
tissue culture plate and individual colonies collected.   
Expression in PC3 cells was induced with 100 μM 
IPTG for two weeks and clones were selected for 100% 
expression, evaluated by flow cytometry (Cytomics ™ 
FC 500, Beckman Coulter Inc. Brea, Ca) using an 
antibody to the HA-epitope (Covance Inc., Emeryville, 
Ca). For flow cytometry, PC3 cell lines expressing both 
isoforms of p53 were fixed with 70% ethanol and 
permeabilised with PBS containing 0.2% Triton X-100. 
Staining was performed using 1:1000 HA-epitope 
antibody and a fluorescent secondary antibody.  
 
To confirm that the cells retained the correct isoform of 
p53, they were analysed by retrotranscription and 
amplification of the gene introduced with the viral 
vector, and digestion with BstUI restriction enzyme. 
PCR yielded a product of about 1,252 bp, as expected, 
and digestion with BstUI produced three fragments 
(722, 284 and 252 bp) from cells transfected with the R 
isoform, and two fragments (722 and 536 bp) from 
those transfected with the P isoform (data not shown), 
confirming the attribution of the isoform expressed by 
the cells.  
 
Immunoprecipitation  and immunoblotting. p53 
expression in PC3 cells was induced with 100 μM 
IPTG. Subconfluent cells were treated with 10 nM 
rotenone (Sigma-Aldrich, Inc. St. Louis, MO) for 72 h. 
Rotenone treated and untreated cells were extracted 
with Lysis Buffer II (Pepscan Presto, Lelystad,The 
Netherlands), sonicated and centrifuged at 4000 x g 
before immunoprecipitation. To immunoprecipitate 
DNA polymerase gamma, 1000 μg of cell extract was 
incubated with 1.6 μg of a rabbit polyclonal antibody 
(Pierce PA121791, Pierce  Rockford, IL, USA) for 5 
hours at 4
o C. The immune complexes were captured 
with protein A/G sepharose. The immunoprecipitates 
were analysed by western blot using an antibody to the 
HA-epitope tag on both p53 isoforms. 
 
mtDNA integrity assessment 
mtDNA copy number.  The mtDNA content was 
measured by real-time PCR on a mtDNA encoded gene 
rarely deleted (ND1) normalised by simultaneous 
measurement of nuclear DNA encoded β actin gene. 
The primers sequences are as follow: ND1: L3485-
ND1_Forward: CCC TAA AAC CCG CCA CAT CT; 
H3532-ND1_Reverse: GAG CGA TGG TGA GAG 
CTA AGG T. β Actin: Forward:  ACC CAC ACT GTG 
CCC ATC TAC; Reverse: TCG GTG AGG ATC TTC 
ATG AGG TA. The quantitative PCR was conducted 
on a Rotor gene Q 6000 system (Qiagen) in a 10 μl 
reaction in different tubes containing 0.3μM each of the 
forward and reverse primer (ND1 and β actin genes), 15 
ng of DNA sample and 1X Mesagreen reaction mix 
(Eurogentec). The PCR condition was set as follow: 
95°C for 5 min, 40 cycles at 95°C 15 s and 60 °C 1 min. 
The Ct Values for both the genes were determined. 
Each measurement was carried out in duplicate and 
repeated three times, the same calibrator sample was 
used in each run. The analysis was performed 
normalising against the calibrator and the result was the 
average of the three repeated experiments. 
 
Nested PCR. A nested PCR analysis was performed to 
screen for low levels of the 4,977 bp deletion in 
mtDNA. Primers and PCR conditions are previously 
reported [34], briefly the PCR condition was: pre-
denaturation at 94°C for 5 min, then 30 cycles at 94°C 
for 10s, 58°C for 45 s and 72°C for 50 s; and a final 
extension at 72°C for 10 min. PCR products were 
visualised in a 2% agarose gel. The presence of the 
4977-bp deletion was indicated by the appearance of a 
358 bp band, which was verified by the presence of a 
positive control sample harbouring the 4,977 bp 
deletion. 
 
Long PCR. The 11.3 kb long-PCR to amplify almost 
full-length of mtDNA was carried out to detect mtDNA 
multiple deletions using forward primer corresponding 
to L-strand nt-3485 to 3519, backward primer H-strand 
nt-14820 to 14786 and Takara LA Taq DNA 
polymerase (Takara Shuzo Corp., Japan) as previously 
reported [48]. Briefly the PCR condition was: pre-
denaturation at 94°C for 3 min, then 30 cycles at 98°C 
for 10s and 68°C for 15 min followed by a final 
extension at 72°C for 12 min. PCR products were 
visualized in a 1% agarose gel. The 11.3-Kb band 
represents the wild type mtDNA, all the other bands 
indicate the deletions. 
 
In vivo correlation between mtDNA heteroplasmy 
and TP53 codon 72 genotype 
Sample. A total of 425 unrelated subjects (191 men and 
234 women, age range 60-108 years; median ages 83.09 
(±15.04) and 86.06 (±13.29) years, respectively) were 
recruited to participate in this study. All the subjects 
were born in Calabria (Southern Italy) and their 
ancestry in the region has been ascertained up to the 
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collected in the frame of several recruitment campaigns 
carried out for monitoring the quality of aging in 
Calabria from 2002. Younger subjects were contacted 
through general physicians. Subjects older than 90 years 
were identified through the population registers and 
then contacted by specialised personnel and invited to 
join the study. Each subject was submitted to a home-
based interview by a trained operator, with the 
administration of a structured questionnaire, validated at 
European level. The questionnaire was aimed to the 
collection of socio-demographic information, evaluation 
of physical, cognitive, depressive status, sensory 
deficits, medications, and self-reported health status. In 
addition, common clinical haematological tests were 
performed. Subjects with dementia and/or neurologic 
disorders were not included. All the subjects had given 
informed consent for studies on aging carried out by our 
research group. White blood cells (WBC) from blood 
buffy coats were used as source of DNA.  
 
p53 codon 72 genotype determination.  DNA was 
extracted using phenol/chloroform, according to standard 
procedures. TP53 genotyping was performed as follows: 
a 156bp sequence containing the polymorphic site was 
amplified by PCR using forward 5' 
GACCCAGGTCCAGATGAAGCT -3' and reverse 5'- 
ACCTACCAGGGCAGCTACGGT-3′ primers. 
Reactions were done in a 50-μL mixture containing DNA 
aliquot (100 ng), 1× PCR buffer, 0.2μM of each primers, 
0.2mM of each dNTP, 1.5mM MgCl2, and 1 U GoTaq 
DNA polymerase (Promega). The PCR conditions were 
set as initial denaturation at 96°C for 3 minutes followed 
by 30 cycles containing 94°C at 30 seconds, 60°C for 30 
seconds, and 72°C for 1 minute. The amplicon was 
digested with 3U of BstUI (Promega) for 4 h at 60ºC and 
the products were analysed on 2% agarose gel. 
 
Quantification of the heteroplasmy by DHPLC.  A 
300bp fragment of the mitochondrial DNA control 
region (nt 16531-261; 300bp) was PCR amplified from 
each DNA sample and submitted to DHPLC as 
previously described in detail [44]. 
 
Statistics. The goodness-of-fit to the Hardy–Weinberg 
equilibrium was calculated by the chi-square test. 
Statistical comparisons by Pearson Chi-Square and 
univariate logistic analysis were performed on SPSS 
15.0 (SPSS Inc., Chicago, IL). p values less than 0.05 
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